Evidence map›Paper›PMID 41088199›Full record

ArticleBMC medical informatics and decision making2025

Ensemble techniques for predictive modeling of leishmanial activity via molecular fingerprints.

Saif Nalband, Pallavi Kiratkar, Maulik Gupta, Mansi Gambhir, Surabhi Sonam, Femi Robert, A Amalin Prince

Abstract read
In one paragraph

Article in BMC medical informatics and decision making, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Saif NalbandDepartment of Computer Science and Engineering, Thapar Institute of Engineering and Technology, Patiala, Punjab, India.
Pallavi KiratkarDepartment of Biology, Indian Institute of Science Education and Research, Pune, Maharashtra, India.
Maulik GuptaDepartment of Computer Science and Engineering, Thapar Institute of Engineering and Technology, Patiala, Punjab, India.
Mansi GambhirDepartment of Biotechnology, Thapar Institute of Engineering and Technology, Patiala, Punjab, India.
Surabhi SonamSchool of Biosciences and Bioengineering, D Y Patil International University, Akurdi, Pune, Maharashtra, India.
Femi RobertDepartment of Electrical and Electronics Engineering, SRM Institute of Science and Technology, Kattankulathur, Tamil Nadu, 603203, India.
A Amalin PrinceDepartment of Electrical and Electronics Engineering, Birla Institute of Technology and Science, Pilani, K K Birla Goa Campus, Zuarinagar, Sancoale, Goa, 403726, India. amalinprince@goa.bits-pilani.ac.in.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundLeishmaniasis, a neglected tropical disease caused by Leishmania protozoan parasites and transmitted by sandflies, poses a significant global health challenge, especially in resource-limited environments. The life cycle of the parasite includes crucial amastigote and promastigote stages, each contributing importantly to the infection process. The current therapies for leishmaniasis face limitations due to considerable side effects and the rise of drug-resistant strains, underscoring the pressing need for new, effective, and safe treatment options. Recent advancements in leishmaniasis vaccine development include live attenuated vaccines, recombinant vaccines, and the use of synthetic biology. These approaches aim to induce robust immune responses while ensuring safety. Controlled human infection studies are also being explored to accelerate vaccine development. However, a licensed vaccine remains elusive.

methodThis study introduces a novel method for drug discovery targeting leishmaniasis, employing machine learning and cheminformatics to forecast the efficacy of compounds against Leishmania promastigotes. A detailed dataset consisting of 65,057 molecules sourced from the PubChem database is utilized, with the Alamar Blue-based assay applied to assess drug susceptibility. The data encoding relies on molecular fingerprints derived from Simplified Molecular Input Line Entry System (SMILES) notations. We employed three distinct fingerprint algorithms, Avalon, MACCS Key, and Pharmacophore, for the development of machine learning models. Various algorithms, including random forest, multilayer perceptron, gradient boosting, and decision tree, are utilized to create models that effectively classify molecules as either active or inactive based on their structural and chemical characteristics, which could significantly impact the drug discovery process for leishmaniasis.

resultsWe additionally introduced a model based on ensembles, achieving a peak accuracy of 83.65% and an area under the curve of 0.8367. This study offers significant promise in enhancing drug discovery efforts focused on tackling the global issue of leishmaniasis.

conclusionFurthermore, the proposed approach has the potential to serve as a framework for addressing other overlooked tropical diseases, offering a promising alternative to conventional drug discovery methods and their associated difficulties.

Indexed as

Antiprotozoal AgentsCheminformaticsDrug DiscoveryLeishmaniaLeishmaniasisMachine LearningDrug ResistanceHumansLife Cycle StagesModels, BiologicalAntiprotozoal AgentsEnsemble learningLeishmananiaMachine learningMolecular fingerprints

Identifiers

PMID41088199
PMCPMC12522471

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.